The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation.

doi:10.1016/S0014-2999(97)83028-2

Paper

The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation.

Published Sep 1, 1997 · David J. Williamson, S. Shepheard, R. G. Hill

European journal of pharmacology

Q1 SJR score

144

Citations

12

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Non-RCT

Animal Study

Highly Cited

Study Snapshot

Rizatriptan effectively reduces neurogenic dural vasodilation and extravasation in rats, potentially contributing to its anti-migraine action.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation.

References

Citations